Pacer Advisors Inc. Trims Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Pacer Advisors Inc. lowered its stake in Omnicell, Inc. (NASDAQ:OMCL) by 39.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,246,520 shares of the company’s stock after selling 823,914 shares during the quarter. Pacer Advisors Inc.’s holdings in Omnicell were worth $54,348,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of OMCL. Nisa Investment Advisors LLC raised its stake in shares of Omnicell by 248.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after acquiring an additional 1,000 shares during the period. GAMMA Investing LLC lifted its stake in Omnicell by 78.4% during the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after purchasing an additional 553 shares in the last quarter. EntryPoint Capital LLC boosted its position in shares of Omnicell by 121.2% during the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock worth $72,000 after buying an additional 1,345 shares during the period. CWM LLC boosted its position in shares of Omnicell by 68.2% during the second quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after buying an additional 1,236 shares during the period. Finally, 1620 Investment Advisors Inc. grew its stake in shares of Omnicell by 230.1% in the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after buying an additional 1,542 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Trading Up 5.5 %

Shares of OMCL stock opened at $44.11 on Friday. Omnicell, Inc. has a 12 month low of $25.12 and a 12 month high of $55.74. The company has a market cap of $2.04 billion, a P/E ratio of -113.10, a PEG ratio of 35.67 and a beta of 0.81. The firm has a fifty day moving average price of $44.19 and a 200 day moving average price of $37.20.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Wells Fargo & Company raised their target price on Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a report on Monday, October 14th. Barclays raised their price objective on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Benchmark reaffirmed a “buy” rating and set a $48.00 target price on shares of Omnicell in a research note on Wednesday, October 9th. Craig Hallum boosted their price target on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, Bank of America reiterated a “neutral” rating and issued a $57.00 price objective (up from $44.00) on shares of Omnicell in a research note on Thursday, October 31st. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $52.00.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.